Depression after covid

Pro Research Analysisby

Searched over 200M research papers

Analyzed relevant papers

Depression After COVID-19: A Comprehensive Overview

Prevalence of Depression Post-COVID-19

Frequency of Depressive Symptoms in Post-COVID-19 Syndrome

Research indicates that a significant number of individuals experience depressive symptoms long after recovering from the acute phase of COVID-19. Studies have shown that the frequency of depressive symptoms 12 weeks post-infection ranges from 11% to 28%, while clinically significant depression affects 3% to 12% of individuals . This highlights the persistent mental health challenges faced by COVID-19 survivors.

Global Prevalence and Comparison with Pre-Pandemic Levels

The global prevalence of depression has surged during the COVID-19 pandemic. A meta-analysis revealed that the pooled prevalence of depression during the pandemic was 25%, which is significantly higher than the pre-pandemic global estimate of 3.44% . This stark increase underscores the profound impact of the pandemic on mental health worldwide.

Depression in Specific Populations

Clinically stable COVID-19 patients also exhibit high rates of depression, with a prevalence of 43.1% . Factors such as having an infected family member, severe COVID-19 infection, and frequent social media use for COVID-19 information were associated with higher depression rates. Additionally, children and adolescents have not been spared, with 25.2% experiencing clinically elevated depression symptoms during the pandemic .

Biomarkers and Etiopathogenesis of Post-COVID Depression

Inflammatory Biomarkers

The search for biomarkers has identified several inflammatory markers associated with post-COVID depression. Elevated levels of interleukin 6 (IL-6), soluble interleukin 6 receptor (sIL-6R), interleukin 1β (IL-1β), tumor necrosis factor α (TNF-α), and other cytokines have been frequently reported . These biomarkers suggest that the etiopathogenesis of post-COVID depression may be linked to the inflammatory response, similar to the leading hypothesis for major depressive disorder (MDD).

Neurobiological Changes

Decreased levels of brain-derived neurotrophic factor (BDNF) and tryptophan (TRP) have also been noted, indicating potential neurobiological changes contributing to depression in COVID-19 survivors . These findings highlight the complex interplay between the immune system and neurobiology in the development of post-COVID depression.

Impact on Quality of Life and Long-Term Mental Health

Quality of Life

Depression significantly impacts the quality of life (QOL) of COVID-19 survivors. Studies have shown that individuals with depression report lower QOL scores compared to those without depression . This emphasizes the need for regular mental health screening and appropriate interventions to improve the overall well-being of COVID-19 survivors.

Long-Term Mental Health Burden

The long-term mental health burden of "Long COVID" is substantial. A study found that 30% of COVID-19 patients exhibited pathological levels of anxiety and depression 1 to 3 months post-virological clearance . Additionally, the prevalence of depression and PTSD in adults discharged from the hospital with COVID-19 was found to be 42% and 96%, respectively . These findings suggest that mental health symptoms are significant and often linked to ongoing physical symptoms such as breathlessness.

Conclusion

The COVID-19 pandemic has led to a marked increase in depression rates globally, with significant long-term mental health implications for survivors. The identification of inflammatory and neurobiological biomarkers provides insights into the potential mechanisms underlying post-COVID depression. Addressing these mental health challenges through regular screening, early diagnosis, and effective treatment is crucial for improving the quality of life and overall well-being of COVID-19 survivors.

Sources and full results

Most relevant research papers on this topic

Onset and frequency of depression in post-COVID-19 syndrome: A systematic review

Post-COVID-19 syndrome occurs in 11-28% of patients, with clinically-significant depression occurring in 3-12%, but severity of acute COVID-19 is not associated with depressive symptoms.

Systematic ReviewHighly Cited

2021·

325citations

·Olivier Renaud-Charest et al.

Journal of Psychiatric Research·

DOI

Biomarkers of Post-COVID Depression

Post-COVID depression is linked to increased levels of inflammatory mediators and decreased brain-derived neurotrophic factors, similar to the leading inflammatory hypothesis of major depressive disorder.

Systematic ReviewRigorous JournalHighly Cited

2021·

85citations

·Piotr Lorkiewicz et al.

Journal of Clinical Medicine·

DOI

Prevalence of depression during the COVID-19 outbreak: A meta-analysis of community-based studies

Introduction COVID-19 pandemic, declared on March 11, 2020, constitute an extraordinary health, social and economic global challenge. The impact on people's mental health is expected to be high. This paper sought to systematically review community-based studies on depression conducted during the COVID-19 and estimate the pooled prevalence of depression. Method We searched for cross-sectional, community-based studies listed on PubMed or Web of Science from January 1, 2020 to May 8, 2020 that reported prevalence of depression. A random effect model was used to estimate the pooled proportion of depression. Results A total of 12 studies were included in the meta-analysis, with prevalence rates of depression ranging from 7.45% to 48.30%. The pooled prevalence of depression was 25% (95% CI: 18%−33%), with significant heterogeneity between studies (I 2 =99.60%, p <.001). Conclusions Compared with a global estimated prevalence of depression of 3.44% in 2017, our pooled prevalence of 25% appears to be 7 times higher, thus suggesting an important impact of the COVID-19 outbreak on people's mental health. Addressing mental health during and after this global health crisis should be placed into the international and national public health agenda to improve citizens’ wellbeing.

Meta-AnalysisVery Rigorous JournalHighly Cited

2020·

736citations

·J. Bueno-Notivol et al.

International Journal of Clinical and Health Psychology : IJCHP·

DOI

Prevalence of depression and its association with quality of life in clinically stable patients with COVID-19

Abstract Introduction : High risk of mental health problems is associated with Coronavirus Disease 2019 (COVID-19). This study explored the prevalence of depressive symptoms (depression hereafter) and its relationship with quality of life (QOL) in clinically stable patients with COVID-19. Methods : This was an online survey conducted in COVID-19 patients across five designated isolation hospitals for COVID-19 in Hubei province, China. Depression and QOL were assessed with standardized instruments. Results : A total of 770 participants were included. The prevalence of depression was 43.1% (95%CI: 39.6%-46.6%). Binary logistic regression analysis found that having family member infected with COVID-19 (OR=1.51, P=0.01), suffering from severe COVID-19 infection (OR=1.67, P=0.03), male gender (OR=0.53, P<0.01), and frequent social media use to obtain COVID-19 related information (OR=0.65, P<0.01) were independently associated with depression. Patients with depression had lower QOL than those without. Conclusion : Depression is highly prevalent in clinically stable patients with COVID-19. Regular screening and appropriate treatment of depression are urgently warranted for this population.

Observational StudyRigorous JournalHighly Cited

2020·

192citations

·Yu-fen Ma et al.

Journal of Affective Disorders·

DOI

Global Prevalence of Depressive and Anxiety Symptoms in Children and Adolescents During COVID-19: A Meta-analysis.

During COVID-19, 1 in 4 youth globally experienced clinically elevated depression symptoms, while 1 in 5 youth experienced clinically elevated anxiety symptoms.

Meta-AnalysisVery Rigorous JournalHighly Cited

2021·

2216citations

·N. Racine et al.

JAMA pediatrics·

DOI

Trajectory curves of post-COVID anxiety/depressive symptoms and sleep quality in previously hospitalized COVID-19 survivors: the LONG-COVID-EXP-CM multicenter study

Post-COVID anxiety/depressive symptoms and sleep quality in hospitalized COVID-19 survivors show varying trends over time.

Rigorous Journal

2022·

31citations

·C. Fernández‐de‐las‐Peñas et al.

Psychological Medicine·

DOI

Anxiety and depression symptoms after virological clearance of COVID‐19: A cross‐sectional study in Milan, Italy

COVID-19 patients with pathological anxiety and depression symptoms may still experience persistent symptoms, highlighting the need for psychological assessments in follow-up care.

Observational StudyHighly Cited

2020·

139citations

·D. Tomasoni et al.

Journal of Medical Virology·

DOI

Prevalence of symptoms of depression, anxiety, insomnia, posttraumatic stress disorder, and psychological distress among populations affected by the COVID-19 pandemic: A systematic review and meta-analysis

Objective . We conducted a systematic review and meta-analysis to estimate the pooled prevalence of depression, anxiety, insomnia, PTSD, and Psychological distress (PD) related to COVID-19 among affected populations. Methods . We searched articles in Medline, Embase, APA PsycInfo, CINAHL, Scopus, and Web of Science. Random-effects meta-analyses on the proportions of individuals with symptoms of depression, anxiety, insomnia, PTSD, and PD were generated and between-group differences for gender, healthcare workers (HCWs), and regions where studies were conducted. Results . A total of 2189 articles were screened, 136 full-text articles were assessed for eligibility. Fifty-five peer-reviewed studies met inclusion criteria for the meta-analysis (N=189,159). The prevalence of depression (k=46) was 15.97% (95%CI, 13.24-19.13). The prevalence of anxiety (k=54) was 15.15% (95%CI, 12.29-18.54). The prevalence of insomnia (k=14) was 23.87% (95%CI, 15.74-34.48). The prevalence of PTSD (k=13) was 21.94% (95%CI, 9.37-43.31). Finally, the prevalence of psychological distress (k=19) was 13.29% (95%CI, 8.80-19.57). Between-group differences were only found in HCWs (z=2.69, p < .05) who had a higher prevalence of insomnia than others. Conclusions . Findings suggest that the short-term mental health consequences of COVID-19 are equally high across affected countries, and across gender. However, reports of insomnia are significantly higher among HCWs than the general population.

Meta-AnalysisRigorous JournalHighly Cited

2020·

808citations

·J. Cénat et al.

Psychiatry Research·

DOI

People with Suspected COVID-19 Symptoms Were More Likely Depressed and Had Lower Health-Related Quality of Life: The Potential Benefit of Health Literacy

Health literacy can protect against depression and improve health-related quality of life in people with suspected COVID-19 symptoms.

Observational StudyRigorous JournalHighly Cited

2020·

487citations

·H. Nguyen et al.

Journal of Clinical Medicine·

DOI

The high mental health burden of “Long COVID” and its association with on-going physical and respiratory symptoms in all adults discharged from hospital

Long COVID" in adults discharged from hospital can lead to significant mental health symptoms and is linked to physical symptoms like breathlessness.

Rigorous JournalHighly Cited

2021·

81citations

·S. Naidu et al.

The European Respiratory Journal·

DOI

Try another search

withdrawal from suboxone

collagen peptides dosage

is hemp oil good for dogs

non small cell lung cancer

how quickly does amlodipine work

what medication increases blood pressure